Citadel Advisors’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-183,300
| Closed | -$1.12M | – | 15475 |
|
|
2021
Q3 | $1.12M | Buy |
183,300
+15,000
| +9% | +$93.5K | ﹤0.01% | 7863 |
|
|
2021
Q2 | $1.39M | Buy |
168,300
+2,700
| +2% | +$23K | ﹤0.01% | 7498 |
|
|
2021
Q1 | $1.48M | Sell |
165,600
-1,600
| -1% | -$18.3K | ﹤0.01% | 7139 |
|
|
2020
Q4 | $1.93M | Sell |
167,200
-900
| -0.5% | -$10.5K | ﹤0.01% | 5427 |
|
|
2020
Q3 | $1.75M | Sell |
168,100
-43,000
| -20% | -$527K | ﹤0.01% | 4980 |
|
|
2020
Q2 | $2.78M | Buy |
211,100
+170,000
| +414% | +$1.76M | ﹤0.01% | 3989 |
|
|
2020
Q1 | $323K | Buy |
41,100
+20,000
| +95% | +$301K | ﹤0.01% | 7199 |
|
|
2019
Q4 | $437K | Buy |
21,100
+10,900
| +107% | +$184K | ﹤0.01% | 7025 |
|
|
2019
Q3 | $140K | Sell |
10,200
-1,900
| -16% | -$22.5K | ﹤0.01% | 8334 |
|
|
2019
Q2 | $149K | Sell |
12,100
-2,700
| -18% | -$31.1K | ﹤0.01% | 8361 |
|
|
2019
Q1 | $185K | Sell |
14,800
-6,600
| -31% | -$88.2K | ﹤0.01% | 8259 |
|
|
2018
Q4 | $242K | Sell |
21,400
-1,200
| -5% | -$18.8K | ﹤0.01% | 7601 |
|
|
2018
Q3 | $423K | Buy |
22,600
+6,100
| +37% | +$140K | ﹤0.01% | 6972 |
|
|
2018
Q2 | $427K | Buy |
+16,500
| New | +$428K | ﹤0.01% | 6635 |
|
|
2017
Q4 | – | Sell |
-30,900
| Closed | -$747K | – | 8625 |
|
|
2017
Q3 | $747K | Sell |
30,900
-21,100
| -41% | -$496K | ﹤0.01% | 4745 |
|
|
2017
Q2 | $1.05M | Sell |
52,000
-12,900
| -20% | -$269K | ﹤0.01% | 4010 |
|
|
2017
Q1 | $1.75M | Buy |
64,900
+47,000
| +263% | +$960K | ﹤0.01% | 3220 |
|
|
2016
Q4 | $340K | Buy |
+17,900
| New | +$342K | ﹤0.01% | 5510 |
|
|
2016
Q2 | – | Sell |
-10,600
| Closed | -$98K | – | 7621 |
|
|
2016
Q1 | $98K | Sell |
10,600
-5,600
| -35% | -$67.9K | ﹤0.01% | 6038 |
|
|
2015
Q4 | $312K | Buy |
+16,200
| New | +$281K | ﹤0.01% | 5164 |
|
Citadel Advisors's FLXN Position: Q4 2021 in Review
Citadel Advisors sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 266,575 shares — an estimated $1.63M sold.
Citadel Advisors first reported a position in FLXN in Q2 2015 and held it in 18 quarters. The position peaked at $5.55M in Q4 2019. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- Citadel Advisors reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- Citadel Advisors sold 266,575 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $1.63M.
- Citadel Advisors first reported a position in Flexion Therapeutics, Inc. in Q2 2015 and held it in 18 quarters.
- Citadel Advisors's Flexion Therapeutics, Inc. position peaked at $5.55M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.